Trial Profile
A Single Center, Open Label, Stepwise, Dose Profiling Study to Evaluate the Efficacy and Safety of Four Dose Regimens of Inhaled TPI ASM8 in Patients With Allergic Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs ASM 8 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Syntara Limited
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
- 04 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Feb 2010 Planned end date changed from 1 Nov 2009 to 1 Feb 2010 as reported by ClinicalTrials.gov.